Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry-Reference-Cited by-同舟云学术

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

Published:2017-09-08 Issue:1 Volume:3 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Stemmer Salomon M.,Steiner Mariana,Rizel Shulamith,Soussan-Gutman Lior,Ben-Baruch Noa,Bareket-Samish Avital,Geffen David B.,Nisenbaum Bella,Isaacs Kevin,Fried Georgeta,Rosengarten Ora,Uziely Beatrice,Svedman Christer,McCullough Debbie,Maddala Tara,Klang Shmuel H.,Zidan Jamal,Ryvo Larisa,Kaufman Bella,Evron Ella,Karminsky Natalya,Goldberg Hadassah,Shak Steven,Liebermann Nicky

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/s41523-017-0034-6.pdf

Reference29 articles.

1. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).

2. Habel, L. A. et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8, R25 (2006).

3. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006).

4. Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65 (2010).

5. Dowsett, M. et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28, 1829–1834 (2010).

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer;npj Breast Cancer;2023-12-14

2. Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry;npj Breast Cancer;2023-09-30

3. Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis;Frontiers in Oncology;2023-06-23

4. Impact of non-adherence to endocrine therapy on recurrence risk in older women with stage I breast cancer after breast-conserving surgery;Breast Cancer Research and Treatment;2023-06-16

5. Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study;npj Breast Cancer;2023-06-02